AAM Backs Bill To Boost Biosimilar Reimbursement
Proposed Legislation Would Temporarily Increase Rate To Average Sales Price Plus 8%
Draft US legislation that would seek to encourage biosimilar adoption by temporarily boosting reimbursement has received the backing of the AAM.
You may also be interested in...
The AAM has urged the US Congress to increase biosimilar reimbursement through higher Medicare Part B add-on payments for biosimilars, based on a recent IQVIA report that has identified a correlation between Medicare payments and biosimilar adoption. The AAM has also urged the CMS to establish a shared savings program.
Hyloris is on a roll with licensing deals for its Maxigesic IV non-opioid pain treatment, with an extension of its existing agreement with Pharma Bavaria to cover South American territories coming hot on the heels of recent developments in the US and Europe.
Australia’s government has agreed to extend a successful biosimilar education initiative led by the local GBMA industry association.